Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.

Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Am J Gastroenterol. 2020 Feb 20. doi: 10.14309/ajg.0000000000000557. [Epub ahead of print]

PMID:
32079858
2.

Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.

Deroo R, Trépo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, Colle I, Van Vlierberghe H, Fallon MB, Raevens S.

Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164. [Epub ahead of print]

PMID:
32017176
3.

Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis.

Muyldermans G, Bielen R, Botterman R, Bourgeois S, Colle I, Deressa B, Devolder G, Horsmans Y, Hutse V, Lanthier N, Lasser L, Platteau S, Robaeys G, Suin V, Verhelst X, Van Vlierberghe H, Van Baelen L.

Acta Gastroenterol Belg. 2019 Oct-Dec;82(4):479-485.

PMID:
31950802
4.

Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury.

Raevens S, Van Campenhout S, Debacker PJ, Lefere S, Verhelst X, Geerts A, Van Vlierberghe H, Colle I, Devisscher L.

J Leukoc Biol. 2020 Feb;107(2):341-355. doi: 10.1002/JLB.5A1119-279R. Epub 2019 Dec 16.

PMID:
31841237
5.

Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases.

Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS.

Gastroenterology. 2020 Jan;158(1):95-110. doi: 10.1053/j.gastro.2019.08.060. Epub 2019 Oct 15. Review.

6.

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.

Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WJ, Parés A, Invernizzi P, Carbone M, Maria Battezzati P, Nevens F, Kowdley KV, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Janssen HLA, Hansen BE, Gulamhusein A; GLOBAL PBC Study Group.

Aliment Pharmacol Ther. 2019 Nov;50(10):1127-1136. doi: 10.1111/apt.15533. Epub 2019 Oct 17.

PMID:
31621931
7.

Update on liver transplantation for cholangiocarcinoma : a review of the recent literature.

Laurent S, Verhelst X, Geerts A, Geboes K, De Man M, Troisi R, Vanlander A, Rogiers X, Berrevoet F, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Jul-Sep;82(3):417-420. Review.

PMID:
31566330
8.

Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis.

Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, Dalekos GN; Global Primary Biliary Cholangitis Study Group.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):684-692.e6. doi: 10.1016/j.cgh.2019.08.013. Epub 2019 Aug 13.

PMID:
31419573
9.

The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation.

Verhelst X, Geerts A, Callewaert N, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):309-313. Review.

PMID:
31314193
10.

Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis.

Goet JC, Floreani A, Verhelst X, Cazzagon N, Perini L, Lammers WJ, de Vries AC, van der Meer AJ, van Buuren HR, Hansen BE.

J Hepatol. 2019 Nov;71(5):992-999. doi: 10.1016/j.jhep.2019.06.012. Epub 2019 Jul 3.

PMID:
31278949
11.

Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders.

Verhelst X, Devolder G, De Wilde M, Goderis L, De Bel A, Spillebeen E, Geerts A, Derese A, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Jan-Mar;82(1):99-100. No abstract available.

PMID:
30888763
12.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028. Epub 2019 Jan 4.

PMID:
30616022
13.

Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, Barea RCR, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Wong F, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bhamidimarri KR, Boyer TD, Maevskaya M, Fassio E, Kim HS, Hwang JS, Gines P, Gadano A, Sarin SK, Angeli P; International Club of Ascites Global Study Group.

Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.

PMID:
30552895
14.

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

Raevens S, Rogiers X, Geerts A, Verhelst X, Samuel U, van Rosmalen M, Berlakovich G, Delwaide J, Detry O, Lehner F, Mittler J, Nadalin S, Nevens F, Pirenne J, Saner F, Schneeberger S, Stippel D, Turk JM, Zoltan M, Troisi RI, Van Vlierberghe H, Colle I.

Eur Respir J. 2019 Jan 31;53(2). pii: 1801096. doi: 10.1183/13993003.01096-2018. Print 2019 Feb. No abstract available.

15.

Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis.

De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X.

Case Rep Gastroenterol. 2018 Oct 2;12(3):597-601. doi: 10.1159/000492204. eCollection 2018 Sep-Dec.

16.

Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.

Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, Hirschfield G, McDowell P, Poupon R, Dumortier J, Bosch A, Giostria E, Conti F, Parés A, Reig A, Floreani A, Russo FP, Goet JC, Harms MH, van Buuren H, Van den Ende N, Nevens F, Verhelst X, Donato MF, Malinverno F, Ebadi M, Mason AL; Global PBC Study Group.

Gastroenterology. 2019 Jan;156(1):96-107.e1. doi: 10.1053/j.gastro.2018.10.001. Epub 2018 Oct 6. Erratum in: Gastroenterology. 2020 Jan;158(1):288.

PMID:
30296431
17.

Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease.

Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L.

Hepatology. 2019 Mar;69(3):1087-1104. doi: 10.1002/hep.30294. Epub 2019 Feb 12.

PMID:
30259536
18.

Endoglycosidase S Enables a Highly Simplified Clinical Chemistry Procedure for Direct Assessment of Serum IgG Undergalactosylation in Chronic Inflammatory Disease.

Vanderschaeghe D, Meuris L, Raes T, Grootaert H, Van Hecke A, Verhelst X, Van de Velde F, Lapauw B, Van Vlierberghe H, Callewaert N.

Mol Cell Proteomics. 2018 Dec;17(12):2508-2517. doi: 10.1074/mcp.TIR118.000740. Epub 2018 Sep 6.

19.

Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium.

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

J Clin Virol. 2018 Jun;103:8-11. doi: 10.1016/j.jcv.2018.03.004. Epub 2018 Mar 19.

PMID:
29602096
20.

Severe Hepatic and Pulmonary Involvement in Rendu-Osler-Weber Syndrome.

Verhelst X, Geerts A, Van Vlierberghe H, Smeets P, Lecluyse C.

Case Rep Gastroenterol. 2018 Jan 17;12(1):13-18. doi: 10.1159/000486189. eCollection 2018 Jan-Apr.

21.

Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction.

Verhelst X, Geerts A, Jochmans I, Vanderschaeghe D, Paradissis A, Vanlander A, Berrevoet F, Dahlqvist G, Nevens F, Pirenne J, Rogiers X, Callewaert N, Troisi RI, Van Vlierberghe H.

Gastroenterology. 2018 Apr;154(5):1361-1368. doi: 10.1053/j.gastro.2017.12.027. Epub 2018 Jan 6.

PMID:
29309776
22.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
23.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

24.

Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool.

Devisscher L, Scott CL, Lefere S, Raevens S, Bogaerts E, Paridaens A, Verhelst X, Geerts A, Guilliams M, Van Vlierberghe H.

Cell Immunol. 2017 Dec;322:74-83. doi: 10.1016/j.cellimm.2017.10.006. Epub 2017 Oct 16.

PMID:
29111158
25.

Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice.

Raevens S, Geerts A, Paridaens A, Lefere S, Verhelst X, Hoorens A, Van Dorpe J, Maes T, Bracke KR, Casteleyn C, Jonckx B, Horvatits T, Fuhrmann V, Van Vlierberghe H, Van Steenkiste C, Devisscher L, Colle I.

Hepatology. 2018 Aug;68(2):634-651. doi: 10.1002/hep.29579. Epub 2018 May 11.

PMID:
29023811
26.

Hepatitis E virus serology and PCR: does the methodology matter?

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

Arch Virol. 2017 Sep;162(9):2625-2632. doi: 10.1007/s00705-017-3395-0. Epub 2017 May 18.

PMID:
28523520
27.

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.

Lefere S, Van de Velde F, Devisscher L, Bekaert M, Raevens S, Verhelst X, Van Nieuwenhove Y, Praet M, Hoorens A, Van Steenkiste C, Van Vlierberghe H, Lapauw B, Geerts A.

Int J Obes (Lond). 2017 Aug;41(8):1207-1213. doi: 10.1038/ijo.2017.102. Epub 2017 May 2.

PMID:
28461687
28.

Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis.

Paridaens A, Raevens S, Devisscher L, Bogaerts E, Verhelst X, Hoorens A, Van Vlierberghe H, van Grunsven LA, Geerts A, Colle I.

Int J Mol Sci. 2017 Jan 20;18(1). pii: E214. doi: 10.3390/ijms18010214.

29.

Refractory subacute steatohepatitis after biliopancreatic diversion.

Lefere S, Hoorens A, Raevens S, Troisi R, Verhelst X, Van Vlierberghe H, Geerts A.

Hepatology. 2017 Jul;66(1):289-291. doi: 10.1002/hep.29038. Epub 2017 May 9. No abstract available.

PMID:
28073162
30.

A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis.

Verhelst X, Vanderschaeghe D, Castéra L, Raes T, Geerts A, Francoz C, Colman R, Durand F, Callewaert N, Van Vlierberghe H.

Clin Cancer Res. 2017 Jun 1;23(11):2750-2758. doi: 10.1158/1078-0432.CCR-16-1500. Epub 2016 Dec 16.

31.

Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication.

Paridaens A, Raevens S, Colle I, Bogaerts E, Vandewynckel YP, Verhelst X, Hoorens A, van Grunsven LA, Van Vlierberghe H, Geerts A, Devisscher L.

Liver Int. 2017 May;37(5):748-756. doi: 10.1111/liv.13261. Epub 2016 Oct 25.

PMID:
27706903
32.

Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.

Bekaert M, Ouwens DM, Hörbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, Geerts A, Verhelst X, Kaufman JM, Lapauw B.

Obesity (Silver Spring). 2016 Dec;24(12):2544-2552. doi: 10.1002/oby.21674. Epub 2016 Oct 21.

33.

Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1.

Van den Borre C, Schuermans W, Van Vlierberghe H, Geerts A, Verhelst X, Padalko E.

J Clin Virol. 2016 Oct;83:54-5. doi: 10.1016/j.jcv.2016.08.291. Epub 2016 Aug 20. No abstract available.

PMID:
27591556
34.

Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form.

Schuermans W, Orlent H, Desombere I, Descheemaeker P, Van Vlierberghe H, Geerts A, Verhelst X, Reynders M, Padalko E.

Int J Mol Sci. 2016 Aug 23;17(9). pii: E1384. doi: 10.3390/ijms17091384.

35.

Quality of life after liver transplantation: State of the art.

Onghena L, Develtere W, Poppe C, Geerts A, Troisi R, Vanlander A, Berrevoet F, Rogiers X, Van Vlierberghe H, Verhelst X.

World J Hepatol. 2016 Jun 28;8(18):749-56. doi: 10.4254/wjh.v8.i18.749. Review.

36.

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.

Vandewynckel YP, Coucke C, Laukens D, Devisscher L, Paridaens A, Bogaerts E, Vandierendonck A, Raevens S, Verhelst X, Van Steenkiste C, Libbrecht L, Geerts A, Van Vlierberghe H.

Oncotarget. 2016 Jun 7;7(23):34988-5000. doi: 10.18632/oncotarget.9222.

37.

Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease.

Lefere S, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Devisscher L, Geerts A.

Cell Mol Life Sci. 2016 Sep;73(18):3419-31. doi: 10.1007/s00018-016-2222-1. Epub 2016 Apr 18. Review.

PMID:
27091156
38.

The role of macrophages in obesity-driven chronic liver disease.

Devisscher L, Verhelst X, Colle I, Van Vlierberghe H, Geerts A.

J Leukoc Biol. 2016 May;99(5):693-8. doi: 10.1189/jlb.5RU0116-016R. Epub 2016 Mar 2. Review.

PMID:
26936934
39.

Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents.

de Clerck F, Geerts A, Brochez L, Speeckaert R, Boterberg T, Van Vlierberghe H, Verhelst X.

J Clin Gastroenterol. 2016 May-Jun;50(5):438. doi: 10.1097/MCG.0000000000000506. No abstract available.

PMID:
26905607
40.

Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis.

Van Biervliet S, Verdievel H, Vande Velde S, De Bruyne R, De Looze D, Verhelst X, Geerts A, Robberecht E, Van Vlierberghe H.

Ultrasound Med Biol. 2016 Apr;42(4):848-54. doi: 10.1016/j.ultrasmedbio.2015.11.011. Epub 2016 Jan 21.

PMID:
26806442
41.

Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma.

Vandewynckel YP, Laukens D, Devisscher L, Bogaerts E, Paridaens A, Van den Bussche A, Raevens S, Verhelst X, Van Steenkiste C, Jonckx B, Libbrecht L, Geerts A, Carmeliet P, Van Vlierberghe H.

BMC Cancer. 2016 Jan 11;16:9. doi: 10.1186/s12885-015-1990-6.

42.

Effect of prolyl hydroxylase domain 2 haplodeficiency on liver progenitor cell characteristics in early mouse hepatocarcinogenesis.

Bogaerts E, Paridaens A, Verhelst X, Carmeliet P, Geerts A, Van Vlierberghe H, Devisscher L.

EXCLI J. 2016 Nov 11;15:687-698. doi: 10.17179/excli2016-607. eCollection 2016.

43.

Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review.

Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P.

Obes Rev. 2016 Jan;17(1):68-80. doi: 10.1111/obr.12333. Epub 2015 Nov 24. Review.

PMID:
26597657
44.

Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure.

Vandewynckel YP, Laukens D, Devisscher L, Paridaens A, Bogaerts E, Verhelst X, Van den Bussche A, Raevens S, Van Steenkiste C, Van Troys M, Ampe C, Descamps B, Vanhove C, Govaere O, Geerts A, Van Vlierberghe H.

Oncotarget. 2015 Sep 29;6(29):28011-25. doi: 10.18632/oncotarget.4377.

45.

IgG4-related cholangitis: Case report and literature review.

De Both A, Van Vlierberghe H, Geerts A, Libbrecht L, Verhelst X.

Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):62-4.

PMID:
26118582
46.

Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving alternative.

Hulstaert E, Verhelst X, Geerts A, Van Vlierberghe H.

J Comp Eff Res. 2015 May;4(3):259-265. doi: 10.2217/cer.15.4. Epub 2015 May 8.

PMID:
25951856
47.

Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors.

Bogaerts E, Heindryckx F, Devisscher L, Paridaens A, Vandewynckel YP, Van den Bussche A, Verhelst X, Libbrecht L, van Grunsven LA, Geerts A, Van Vlierberghe H.

PLoS One. 2015 Mar 20;10(3):e0119555. doi: 10.1371/journal.pone.0119555. eCollection 2015.

48.

Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment.

Raevens S, Geerts A, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Colle I.

Liver Int. 2015 Jun;35(6):1646-60. doi: 10.1111/liv.12791. Epub 2015 Feb 16. Review.

PMID:
25627425
49.

Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy.

Vandewynckel YP, Laukens D, Bogaerts E, Paridaens A, Van den Bussche A, Verhelst X, Van Steenkiste C, Descamps B, Vanhove C, Libbrecht L, De Rycke R, Lambrecht BN, Geerts A, Janssens S, Van Vlierberghe H.

Hepatol Int. 2014 Oct 1;9(1):93-104. doi: 10.1007/s12072-014-9582-0. eCollection 2015 Jan.

50.

Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma.

Vandewynckel YP, Geerts A, Verhelst X, Van Vlierberghe H.

Clin Case Rep. 2014 Feb;2(1):4-6. doi: 10.1002/ccr3.34. Epub 2013 Dec 31.

Supplemental Content

Loading ...
Support Center